HOME >> MEDICINE >> NEWS
Anti-coagulation drugs found to have different effects in diabetics after heart attack

CHICAGO -- In a sub-analysis of data from an earlier trial comparing the ability of three agents used to restore blood flow to patients soon after heart attacks, researchers have found that drugs used to prevent blood coagulation appear to have different effects in heart patients with diabetes.

These findings, coupled with an assessment of ease of administration and cost compared to other drugs, leads researchers from Duke University Medical Center to recommend the drug enoxaparin, which is a low-molecular weight heparin, for acute heart attack patients with diabetes.

The Duke team reported the results of its analysis today (Nov. 20, 2002) at the 75th annual scientific session of the American Heart Association.

When heart attack patients are rushed to the emergency room, physicians immediately try to restore blood flow to the heart, usually by giving medications that dissolve clots in the coronary arteries. Since no one drug has been totally effective on its own in opening clogged arteries and keeping them open, researchers have tried different combinations of agents.

Thus was born the ASSENT-3 trial, the results of which were published in August 2001 in the journal Lancet. The trial enrolled 6,116 patients and documented the combined rates of death, recurrent heart attack or refractory chest pain. They then used this composite endpoint to measure the effectiveness of three different combinations of drugs.

All patients entered the hospital within six hours of a heart attack and were given varying doses of tenecteplase, a genetically altered version of the well-known clot-buster t-PA, which quickly dissolves the blood clot. Patients were then randomized to receive additional agents intended to keep the vessels clear: the blood-thinner enoxaparin; the blood-thinner unfractionated heparin plus abciximab (an agent that keeps platelets in the blood from clumping); or unfractionated heparin alone.

ASSENT-3 found that both th
'"/>

Contact: Richard Merritt
merri006@mc.duke.edu
919-684-4148
Duke University Medical Center
20-Nov-2002


Page: 1 2 3

Related medicine news :

1. UW research shows risk factors for relapse among health care professionals who abuse drugs
2. New studies show mixed results on epilepsy drugs and birth defects
3. Newly discovered pathway might help in design of cancer drugs
4. Study examines consequences of Thailands war on drugs
5. Computational tool predicts how drugs work in cells, advancing efforts to design better medicines
6. Three anti-platelet drugs used in combination are safe
7. HIV patients may be at risk of heart problems when taking protease inhibitor drugs
8. Clot-busting drugs may help detect potentially deadly leg clots
9. Herb used to treat diabetes works like modern-day prescription drugs, study suggests
10. Penn study shows how next-generation diabetic drugs could work more selectively
11. Study shows drugs such as Vioxx and Celebrex were widely over-used long before recent problems

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... ... Odds, are scheduled to provide a unique keynote address at the 2016 ... the inspirational stories of five community college students. Their stories—of complicated family issues, ...
(Date:5/6/2016)... Milford, PA (PRWEB) , ... May 06, 2016 ... ... CoolSculpting does to reduce fat areas around the body, is the most ... The survey results just released make perfect sense to cosmetic surgeon Dr. Richard ...
(Date:5/6/2016)... ... ... Mark Black is a speaker, author, and life strategy coach who is spreading the ... help of his publisher Strategic Book Group and its subsidiary Publish on Demand Global ... a miracle: He needed a heart and double-lung transplant. From this came a life-changing transformation ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... Sovaldi, which made headlines mostly for its cost despite its potential to wipe ... questions surrounding the drug—part of a class called direct-acting antivirals (DAAs)—have created fallout ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... President at CareFirst Blue Cross BlueShield and Former Principal Deputy Administrator at Centers ... - an Anthem Company; Steve Ondra, MD, Chief Medical Officer at Health Care ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 2016 In March, 2016, ... of free workshops across Africa ... for Good Distribution Practices (GDP). Good Distribution Practice ... products are consistently stored, transported and handled under suitable ... specification. Only a few years ago, there were ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Multiple Myeloma Market and ... their offering.       (Logo: ... Market and Competitive Landscape Highlights 2016, provides ... Multiple Myeloma epidemiology, Multiple Myeloma market valuations ...
(Date:5/4/2016)... DUBLIN , May 4, 2016 /PRNewswire/ ... the addition of the  "Global Acute Myeloid ... 2016"  report to their offering.  ... ,Global Acute Myeloid Leukemia Market and Competitive ... Acute Myeloid Leukemia pipeline products, Acute Myeloid ...
Breaking Medicine Technology:
Cached News: